Screener
DexCom DXCM Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by DexCom in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: DexCom’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001093557-26-000073
| (In millions, except share and par value data) | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $2,073.9 | $1,944.0 |
| Accrued payroll and related expenses | 121.8 | 169.2 |
| Short-term operating lease liabilities | 20.5 | 21.6 |
| Other current liabilities | 7.6 | 7.7 |
| Total current liabilities | 2,223.8 | 2,142.5 |
| Long-term senior convertible notes | 1,241.8 | 1,240.9 |
Item 1. Financial Statements
FAQ
- What is DexCom's accrued manufacturing costs?
- DexCom (DXCM) reported accrued manufacturing costs of $121.8M in Q1 2026.
- How has DexCom's accrued manufacturing costs changed year-over-year?
- DexCom's accrued manufacturing costs increased by 9.9% year-over-year, from $110.8M to $121.8M.
- What is the long-term trend for DexCom's accrued manufacturing costs?
- Over 5 years (2020 to 2025), DexCom's accrued manufacturing costs has grown at a 8.2% compound annual growth rate (CAGR), from $114.3M to $169.2M.
Ask your AI about DexCom's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude